Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VSJ-110 · 2 trials · 2 indications
Corneal Staining will be assessed by the investigator on a scale of 0-4, with a higher number indicating a higher grade of staining.
Change from baseline in ocular itching evaluated by the subject at 3(±1), 5(±1), and 7(±1) minutes post allergen challenge (0-4 scale, with a higher number indicating more itching)
Change from baseline in conjunctival redness evaluated by the investigator at 7 (±1), 15 (±1), and 20 (±1) minutes post allergen challenge (0-4 scale, with a higher number indicating more redness)
| Arm | Type | Description |
|---|---|---|
| VSJ-110 Solution | EXPERIMENTAL | - |
| Placebo Solution | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| VSJ-110 | DRUG | ophthalmic solution |
| Placebo | DRUG | ophthalmic solution |
Inclusion Criteria: * Be at least 18 years of age of either gender and any race. * Provide written informed consent and sign the HIPAA form. * Be willing and able to follow all instructions and attend all study visits. Exclusion Criteria: * Use of any of the disallowed medications during the wash...
VSJ-110 is an investigational small molecule being developed for the treatment of dry eye and allergic conjunctivitis. It is currently in Phase 2 clinical trials for both ophthalmic conditions.
VSJ-110 targets CFTR, a protein involved in ion transport. It is being studied as a potential treatment for dry eye and allergic conjunctivitis.
VSJ-110 is being developed by Vanda Pharmaceuticals Inc., a biopharmaceutical company traded on NASDAQ under the ticker VNDA.
VSJ-110 is in Phase 2 clinical development. It is not FDA approved and remains investigational for the treatment of dry eye and allergic conjunctivitis.
VSJ-110 has two Phase 2 trials. NCT04622345, a completed study in allergic conjunctivitis with 47 participants, and NCT07179055, a recruiting study in dry eye with an enrollment of 160 participants. Both are randomized, double-blind, and placebo-controlled.
VSJ-110 is the sole name provided for this investigational compound. No alternative names have been reported for this drug candidate.